Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Octanine
(human plasma derived coagulation factor IX) /
Octapharma
Welcome,
Profile
Billing
Logout
0 Diseases
0 Trials
0 Trials
1 News
||||||||||
Octanine
(human plasma derived coagulation factor IX) /
Octapharma
[VIRTUAL] Prospective, Open-label, Multicentre Phase II Study (PeKaFIX) to Evaluate the Pharmacokinetic Parameters of a Plasma Derived Factor IX Concentrate and Build a Pharmacokinetic Bayesian Model
(Room 3) - Jun 9, 2021 - Abstract #ISTH2021ISTH_863;
Conclusions : OCTANINE® has a terminal half-life of 35 hours after a single administration. The FIX model enables sparse sampling data to be used to individualise OCTANINE® prophylaxis and suggests that some patients could be treated with less frequent injections to maintain a trough level above 1%.